Breast Cancer Clinical Research Unit

Miguel Angel Quintela Head of Clinical Research Unit
T +34 917328000 (Ext 2930)
mquintela@cnio.es

Staff Scientists

Clinical Research Fellow

Jorge Silva

Post-Doctoral Fellows

Rebeca Gema Jimeno

Graduate Students

Sara Fernández
José Luis Ruiz

Technicians

The Breast Cancer Clinical Research Unit (BCCRU) focuses on the translational interface of therapeutic development. Breast cancer is a heterogeneous disease and, thus, there are large inter-patient variations in terms of disease course, prognosis, relapse and resistance to conventional or targeted therapeutics.

Our activities are directed towards personalised treatment, and they range from preclinical models to the sponsoring of multicentric clinical trials. Specifically, our research areas are:

Discovery of new targets for breast cancer prevention.
Breast cancer functional taxonomy: by using a systems biology approach, we are clustering the disease into subtypes defined by biological features that constitute therapeutic targets.
Study of the mechanisms of resistance against targeted therapies.

Publications

Quintela-Fandino M, Morales S, Cortés-Salgado A, Manso L, Apala JV, Muñoz M, Gasol Cudos A, Salla Fortuny J, Gion M, Lopez-Alonso A, Cortés J, Guerra J, Malón D, Caleiras E, Mulero F, Mouron S (2020). Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer.. Clin Cancer Res 26, 35-45. CNIO Publication.
Bueno MJ, Jimenez-Renard V, Samino S, Capellades J, Junza A, López-Rodríguez ML, Garcia-Carceles J, Lopez-Fabuel I, Bolaños JP, Chandel NS, Yanes O, Colomer R, Quintela-Fandino M (2019). Essentiality of fatty acid synthase in the 2D to anchorage-independent growth transition in transforming cells.. Nat Commun 10, 5011. CNIO Publication. Open Access
Morales ML, Arenas A, Ortiz-Ruiz A, Leivas A, Rapado I, Rodríguez-García A, Castro N, Zagorac I, Quintela-Fandino M, Gómez-López G, Gallardo M, Ayala R, Linares M, Martinez-Lopez J (2019). MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia. Sci Rep 9, 18630. CNIO Publication. Open Access
Zagorac I, Fernandez-Gaitero S, Penning R, Post H, Bueno MJ, Mouron S, Manso L, Morente MM, Alonso S, Serra V, Muñoz J, Gómez-López G, Lopez-Acosta JF, Jimenez-Renard V, Gris-Oliver A, Al-Shahrour F, Piñeiro-Yañez E, Montoya-Suarez JL, Apala JV, Moreno-Torres A, Colomer R, Dopazo A, Heck AJR, Altelaar M, Quintela-Fandino M (2018). In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer. Nat Commun 9, 3501. CNIO Publication. Open Access
Álvarez-Fernández M, Sanz-Flores M, Sanz-Castillo B, Salazar-Roa M, Partida D, Zapatero-Solana E, Ali HR, Manchado E, Lowe S, VanArsdale T, Shields D, Caldas C, Quintela-Fandino M, Malumbres M (2018). Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer. Cell Death Differ 25, 828-840. CNIO Publication.
Quintela-Fandino M, Lluch A, Manso LM, Calvo I, Cortes J, Garcia Saenz JA, Gil JM, Martinez-Jez N, Gonzalez Martin A, Adrover E, De Andres R, Viñas G, Llombart-Cussac A, Alba E, Guerra K, Bermejo B, Zamora E, Moreno-Anton F, Pernas Simón S, Carrato A, Lopez A, Escudero MJ, Campo R, Carrasco EM, Palacios J, Mulero F, Colomer R (2017). 18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: a window-of-opportunity randomized trial.. Clin Cancer Res 23, 1432-1441. CNIO Publication.
Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer. (2017). Álvarez-Fernández M, Sanz-Flores M, Sanz-Castillo B, Salazar-Roa M, Partida D, Zapatero-Solana E, Ali HR, Manchado E, Lowe S, VanArsdale T, Shields D, Caldas C, Quintela-Fandino M, Malumbres M.. Cell Death Differ (in press). CNIO Publication.
Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Català I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, García N, Perkins AS, Bonifaci N, Skowron M, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Serrat X, Cerón J, Brunet J, Barretina MP, Gil M, Falo C, Fernández A, Morilla I, Pernas S, Plà MJ, Andreu X, Seguí MA, Ballester R, Castellà E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Sánchez-Mut JV, Sánchez-Céspedes M, Cordero A, Gómez-Miragaya J, Palomero L, Gómez A, Gajewski TF, Cohen EEW, Jesiotr M, Bodnar L, Quintela-Fandino M, López-Bigas N, Valdés-Mas R, Puente XS, Viñals F, Casanovas O, Graupera M, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Martín-Martín N, Matheu A, Carracedo A, González-Suárez E, Nanjundan M, Cortés J, Lázaro C, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA. (2017). Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.. Oncogene 36, 2737-2749. CNIO Publication.
Bueno MJ, Mouron S, Quintela-Fandino M. (2017). Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach.. Br J Cancer 116, 1119-1125. CNIO Publication.
Quintela-Fandino M, Soberon N, Lluch A, Manso L, Calvo I, Cortes J, Moreno-Antón F, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, Adrover E, de Andres R, Viñas G, Llombart-Cussac A, Alba E, Mouron S, Guerra J, Bermejo B, Zamora E, García-Saenz JA, Simon SP, Carrasco E, Escudero MJ, Campo R, Colomer R, Blasco MA (2017). Critically short telomeres and toxicity of chemotherapy in early breast cancer. Oncotarget 8, 21472-21842. CNIO Publication.
Mateo F, Arenas E, Aguilar H, Serra-Musach J, Ruiz de Garibay G, Boni J, Maicas M, Du S, Iorio F, Herranz C, Isam A, Prado X, Llorente A, Petit A, Vidal A, Catala I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts A, Weerd V, Look MP, Puertas S, GArcia N, Perkins AS, Bonifaci N, Skowron M, Gomez-Baldo L, Hernandez V, Martinez A, Martinez-Iniesta M, Serrat X, Ceron J, Brunet J, Barretina MP, Gil M, Falo C, Fernandez A, Morilla I, Pernas S, Pla MJ, Andreu X, Seguí MA, Ballester R, Castellá E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Sanchez-Mut JV, Gonzalez-Suarez E, Cordero A, Sanchez Cespedes M, Gajewski TF,Cohen EEZ, Jesiotr M, Bodnar L, Quintela-Fandino M, Lopez-Bigas N, Viñals F, Casanovas O, Graupera M, Hernandez-Losa J, Ramon y Cajal S, Saez-Rodriguez J, Esteller M, Sierra A, Martin-Martin N, Matheu A, Carracedo A, Nanjundan M, Cortes J, Odero M, Lazaro C, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA (2016). Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.. Oncogene (in press). CNIO Publication.
Hernández-Agudo E, Mondejar T, Soto-Montenegro ML, Megías D, Mouron S, Sanchez J, Hidalgo M, Lopez-Casas PP, Mulero F, Desco M, Quintela-Fandino M (2016). Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET. Mol Oncol 10, 1704-1718. CNIO Publication. Open Access
Manso L, Mourón S, Tress M, Gómez-López G, Morente M, Ciruelos E, Rubio-Camarillo M, Rodriguez-Peralto JL, Pujana MA, Pisano DG, Quintela-Fandino M (2016). Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance.. PLoS ONE 11, e0155840. CNIO Publication.
Bueno M, Sanchez J, Colomer R, Quintela-Fandino M. (2016). Antiangiogenics and hypoxic response: Role of fatty acid synthase inhibitors.. Curr Drug Targets 17, 1735-1746. CNIO Publication.
Ebos J, Quintela-Fandino M (2016). Revisiting the revolution: examining the evolving role of antiangiogenic therapy in cancer.. Curr Drug Targets 17, 1706. CNIO Publication.
Lord S, Funes JM, Harris AL, Quintela-Fandino M (2016). Antiangiogenic resistance and cancer metabolism: opportunities for synthetic lethality.. Curr Drug Targets 17, 1714-1727. CNIO Publication.
Navarro P, Bueno MJ, Zagorac I, Mondejar T, Sanchez J, Mourón S, Muñoz J, Gómez-López G, Jimenez-Renard V, Mulero F, Chandel NS, Quintela-Fandino M (2016). Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics. Cell Reports 15, 2705-2718. CNIO Publication. Open Access
Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Viale G, Cameron D; Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration. (2015). Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.. Ann Oncol 26, 1280-1291. CNIO Publication.
Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF; Residual Disease Characterization Working Group of the Breast International Group-North American Breast Cancer Group Collaboration. (2015). Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.. Mod Pathol 28, 1185-1201. CNIO Publication.